Skip to main content
NUTX logo

NUTX · Nutex Health Inc.

Track NUTX — free
$162.64 +0.54 (+0.33%) At close · Nov 20
Market Cap
$1.12B
Shares
6.86M
Volume · Nov 20 157.56K Avg daily vol (3M) 149.54K

Price & Indicators

 

Key stats

Close
$162.64
Fri 20 Nov
Open
$158.62
Fri 20 Nov
Average volume, 30 days
135K
shares a session
Short interest
1.2M
17.0% of shares · 10.1 days to cover
Day range
$155.04$165.79
Open $158.62 Close $162.64
52-week closing range
$87.01$225.00
Close $162.64 27.7% under the high
Short volume, last session
69%
Last earnings
Nov 6, 2026
Latest filing
10-Q · Nov 5
Price history
Apr 2022 to Nov 2026

Up next

Mar 5, 2027 Est · unconfirmed · in 15 wks
call held May 1, 2026

Latest documents

2026
Nov 17
Current report 8-K Events of Nov 16
Board declares special $2.00 per share cash dividend, payable December 14, 2026

The board declared a special cash dividend of $2.00 per share, payable December 14, 2026 to holders of record as of November 30, 2026. Payment is conditioned on delivery of a customary CFO certificate, and the board may revoke or modify the dividend before payment.

Other events
3 source passages
the Board of Directors declared a special cash dividend of $2.00 per share of the Company's common stock The Dividend is payable on December 14, 2026 to stockholders of record as of the close of business on November 30, 2026. the Board has reserved the right to revoke or modify the Dividend prior to the payment date. Open the document at this passage
Nov 5
Current report 8-K
Nine-month net income rises 159% despite revenue decline

Nutex Health reported nine-month 2026 revenue of $644.9 million, down 10.9%, while net income attributable to Nutex Health rose 159% to $152.9 million and operating cash flow reached $188.1 million.

Financial results
3 source passages
Total revenue decreased 10.9% to $644.9 million for the nine months ended September 30, 2026, compared to $723.6 million for the same period in 2025, while hospital division revenue at same hospitals decreased 11.2%. Net income attributable to Nutex Health increased 159% in the first nine months of 2026 as compared to the same period in 2025, primarily due to lower stock-based compensation related to obligations for under-construction and ramping hospitals. “2026 is continuing to be a solid financial year, including total revenue of $644.9 million, net income attributable to Nutex of $152.9 million, diluted EPS of $21.50 per share, and $188.1 million of operating cash flow in the first nine months of 2026. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Arbitration costs totaled $61.4 million for nine months

Nutex Health’s arbitration costs totaled $27.8 million for the three months ended September 30, 2026 and $61.4 million for the nine months ended September 30, 2026, compared with $41.9 million and $116.2 million, respectively, in 2025.

Revenue $217.61M ▼ 18.7% Net income $40.23M ▼ 27.4% Diluted EPS $5.71 ▼ 26.4%
Read from the MD&A section
Source passage
The total cost of arbitration for all Nutex hospital and professional services for the three months ended September 30, 2026 and 2025 totaled $27.8 million and $41.9 million, respectively, and for the nine months ended September 30, 2026 and 2025 totaled $61.4 million and $116.2 million, respectively. Open the document at this passage
Sep 11
Current report 8-K Events of Sep 10
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$796.53M
Trailing 12 months
Net income (TTM)
$101.28M
Trailing 12 months
Revenue growth YoY
-18.7%
Year over year
Operating margin
39.0%
Trailing 12 months
P / E (TTM)
6.8
Trailing earnings · reciprocal yield 14.7%
FCF yield
22.2%
TTM · current market cap
Return on invested capital
108.8%
Trailing 12 months
Net cash
$207.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.9%
Year over year · fewer shares
Price change (1Y)
+14.3%
Trailing year
Short interest
17.0%
Latest settlement · 10.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg −19%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 55%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −22%
trailing
6-month return +30%
trailing
YTD return −1%
this year
Relative strength +39%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $200 › 200d $153 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +45 funds added
Insider flow Distributing
Net -$43.5K over 90 days · 100% sells
Short interest Falling
16.97% of shares out · ▼ -5.9% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
184 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth +82%
Y/Y
Gross margin 51%
expanding
EPS growth +8%
Y/Y
Free cash flow $245.6M
Buyback $19.8M
remaining
Balance sheet $143.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −54%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
−19% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $200 › 200d $153 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +45 funds added
Insider flow Distributing
Net -$43.5K over 90 days · 100% sells
Short interest Falling
16.97% of shares out · ▼ -5.9% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
184 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $87 Now $163 · 55% Range high $225
vs 200-day avg +6% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
EBITDA attributable to Nutex Health non-GAAP $225.8M nine months ended September 30, 2026 —
Total cost of arbitration $61.4M nine months ended September 30, 2026 —
Hospital facilities 27 as of the filing date —
Patient visits 49,962 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NUTX
Nutex Health Inc.
this stock
$1.12B -1.2% +82.4% — 17.0%
HCA
HCA Healthcare, Inc.
$99.34B +1.9% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$31.59B -2.2% — — 0.0%
THC
Tenet Healthcare Corp
$20.95B +32.4% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$13.11B +25.9% +10.5% 20.9 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
184
% held
46.1%
Net QoQ
+225.5K sh
Top holder
Pertento Partners LLP
Held Float
View
Held by Funds
Fund positions
168
View
Short & Settlement
Short Interest Falling
Shares short
1.2M
Days to cover
10.1d
Change
-72.5K sh
View
Short Volume
Short vol %
69%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
291
Value
$61.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
42.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$43.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$875.3M
Net income (FY)
$70.8M
EPS diluted
$10.48
View
Buybacks
Authorized
$25.0M
Remaining
$19.8M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 17, 2026
This year
17

The board declared a special cash dividend of $2.00 per share, payable December 14, 2026 to holders of record as of November 30, 2026. Payment is conditioned on delivery of a customary CFO certificate, and the board may revoke or modify the dividend before payment.

View
Exempt Offerings
Offering
$15.0M
Filed
Oct 17, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
Nutex Health Declares First Divid…
Published
Nov 17, 2026
View

Performance

5D 20D 120D MTD YTD
NUTX -6.4% -22.4% +30.1% -18.7% -1.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.2% -13.2% +39.3% -10.0% -2.4%

Capital returns

Declared · upcoming
$2.00 / share · ex Nov 30, 2026
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Buyback program · as of Jun 30, 2026
Authorized
$25.00M
Spent (derived)
$5.20M
Remaining
$19.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1479681 CUSIP 67079U306 13F (30d) 181 filings 167 filers Visit website Investor relations